WallStSmart

Cross Country Healthcare Inc (CCRN)vsEli Lilly and Company (LLY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 8529% more annual revenue ($86.46B vs $1.00B). LLY leads profitability with a 31.9% profit margin vs -9.8%. LLY appears more attractively valued with a PEG of 1.36. LLY earns a higher WallStSmart Score of 74/100 (B).

CCRN

Hold

36

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.25

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCRNUndervalued (+37.2%)

Margin of Safety

+37.2%

Fair Value

$13.16

Current Price

$13.25

$0.09 discount

UndervaluedFair: $13.16Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCRN3 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2510/10

Safe zone — low bankruptcy risk

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.26T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
53.7%10/10

Strong operational efficiency at 53.7%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$7.76B8/10

Generating 7.8B in free cash flow

Areas to Watch

CCRN4 concerns · Avg: 2.3/10
Market CapQuality
$428.06M3/10

Smaller company, higher risk/reward

PEG RatioValuation
12.622/10

Expensive relative to growth rate

Return on EquityProfitability
-31.5%2/10

ROE of -31.5% — below average capital efficiency

Revenue GrowthGrowth
-17.8%2/10

Revenue declined 17.8%

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.623/10

Elevated debt levels

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.2x2/10

Trading at 31.2x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CCRN

The strongest argument for CCRN centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.

Bear Case : CCRN

The primary concerns for CCRN are Market Cap, PEG Ratio, Return on Equity.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

CCRN profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.

LLY carries more volatility with a beta of 0.45 — expect wider price swings.

LLY is growing revenue faster at 38.6% — sustainability is the question.

LLY generates stronger free cash flow (7.8B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (74/100 vs 36/100), backed by strong 31.9% margins and 38.6% revenue growth. CCRN offers better value entry with a 37.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cross Country Healthcare Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cross Country Healthcare, Inc. provides talent management and other consulting services for healthcare clients in the United States. The company is headquartered in Boca Raton, Florida.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?